Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatism’s Congress

June 8, 2011 By Bio-Medicine.Org

NEW YORK, June 8, 2011 /PRNewswire/ — One of the major annual
rheumatology conferences, the European League Against Rheumatism’s
Congress (EULAR), was held May 25-28 in London.  Citeline,
Inc., reviewed the trends and highlights from clinical trial
results reported at EULAR, noting that approved biologics in
rheumatoid arthritis dominated the program, comprising roughly 25%
of clinical trial abstracts presented.  

Updates from long-term trials for approved biologics in
RA—including adalimumab, etanercept, abatacept, rituximab and
tocilizumab—provided further evidence of sustained clinical
efficacy by standard measures, but also extended to reductions in
joint damage (by radiographic and MRI methodologies), remission
induction and effective treatment of early disease.  Of these
approved biologics, tocilizumab trial results were the most
numerous, and included several reports of treatment impact on serum
lipid levels and other cardiovascular-related outcomes.  

Citeline’s Senior Analyst in Autoimmune/Inflammation, Claire
Herman, noted that the industry-wide interest in personalized
medicine was evident at EULAR, with an array of abstracts
presenting results from studies aimed at identifying biomarkers and
pharmacogenomic markers as predictors of response to specific
approved biologics. “This research is indicative of companies’
focus on carving out individual niches within this highly
competitive chronic disease arena,” remarks Ms. Herman.  

Additionally, a number of these approved drugs’ sponsors
continue to focus on life-cycle management and expanded labeling,
as evidenced by abstracts reporting results from trials of the
subcutaneous formulation of abatacept (ALLOW and ACQUIRE), pivotal
trials for Japanese approval of golimumab for RA, tocilizumab
juvenile RA studies (TENDER), and rituximab combination therapies
results. Trends in Trials for Approved Biologic Therapies in
Rheumatoid ArthritisNumber of ab

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of ResMed President and COO Rob Douglas
ResMed finds a solution to semiconductor shortage, as well as some humor in it
Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech